Panbela Therapeutics, Inc. has filed a prospectus supplement on July 30, 2024, to update and supplement information related to the issuance of 4,776,038 shares of common stock underlying previously issued warrants. This filing is in conjunction with a current report on Form 8-K, which details the company's entry into a Loan Agreement with USWM, LLC on July 24, 2024. Under the agreement, Panbela Therapeutics and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., have secured a term loan of $1.5 million, with a maturity date linked to the occurrence of a Qualifying Financing or Transaction by December 31, 2024, or July 24, 2025, respectively. The loan is accompanied by an interest and premium payment structure and is secured by a first priority security interest in the company's rights in an...Show More

Panbela Therapeutics, Inc. has filed a prospectus supplement on July 30, 2024, to update and supplement information related to the issuance of 4,776,038 shares of common stock underlying previously issued warrants. This filing is in conjunction with a current report on Form 8-K, which details the company's entry into a Loan Agreement with USWM, LLC on July 24, 2024. Under the agreement, Panbela Therapeutics and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., have secured a term loan of $1.5 million, with a maturity date linked to the occurrence of a Qualifying Financing or Transaction by December 31, 2024, or July 24, 2025, respectively. The loan is accompanied by an interest and premium payment structure and is secured by a first priority security interest in the company's rights in an Asset Purchase Agreement. The proceeds from the loan are designated for specific uses, including payment of fees to a contract research organization and other working capital purposes. The company's common stock is quoted on the OTCQB under the symbol 'PBLA', with the last reported sales price being $0.35 per share as of July 29, 2024.